ArticleEJHaemPublished
Efficacy and Safety of Teclistamab in Relapsed/Refractory Multiple Myeloma: 2-Year Follow-Up From MajesTEC-1 China Cohort
Regional connection
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
- Institution
- Johnson & Johnson
- County
- Montgomery County
Publication record
- Type
- Article
- Venue
- EJHaem
- Published
- Topic
- Clinical care
- Subject terms
- Bispecific antibody; Relapsed/refractory Multiple Myeloma; Teclistamab; Majestec‐1 Study
- PubMed ID
- 42534634
- PubMed Central ID
- PMC13421914
- Open access
- Yes, open
- Added to directory
- Source checked